UCL Cancer Institute


Home - Euro Ewing Consortium

The EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (EEC project) was a UCL coordinated collaborative project involving 20 European partners, and was awarded funding through the European Union's Framework Programme 7 (FP7). The EU-funded project ended in September 2019 but the EEC is continuing thanks to the generous support of Bone Cancer Research Trust and the Ewing's Sarcoma Research Trust. The EEC will maintain and expand the collaborative activities established over the seven years with the continued aim of improving survival from Ewing sarcoma.

Ewing Sarcomas (ES) are fatal, rare bone cancers particularly affecting young people. About 60% of patients achieve long term survival with current treatment but there has been no improvement in this proportion for 25 years. Treatment is unsuccessful because chemotherapy fails to prevent the development of, or to effectively treat established, metastases.

The Euro Ewing Consortium is a coalition of clinical study groups bringing together the most active clinicians and scientists in Europe dedicated to improving survival from ES. The EU-funded project supported an integrated programme of investigator-driven, inclusive clinical trials that were rigorously designed, conducted, analysed and reported, and underpinned by complementary embedded translational research. Through collaborative working, the EEC provided ES patients with greater access to clinical trials, allowed efficient acquisition of knowledge and delivered clinically meaningful results that will contribute to improved survival from ES.

EEC strategy and priorities

The EEC Executive has approved the following strategy to direct the work of the EEC over the next three years (EEC strategy 2021 (pdf)).

The priorities for the EEC are: 

  1. Harmonisation
  2. Better treatments
  3. Support global efforts – collaboration will benefit European patients and worldwide patients
  4. Funding

EEC Newsletter - December 2021

The fourth newsletter of the new era of the EEC can be viewed here.

The next EEC meeting will be held virtually on Zoom on Tuesday 25 January 2022. The agenda can be found here and registration is through Eventbrite.



Registration is open for the "100 Years Ewing Sarcoma Scientific Meeting", December 10 &11 2021 in Essen/Germany - hybrid meeting

The meeting will take place from December 10, from 1pm CET to December 11, 2021, 1pm CET (agenda) and will be held as a hybrid meeting at the University Hospital Essen, with live streaming of the presentations. The meeting will be held to honor the “Cancer Man” James Ewing, who described the “Ewing Sarcoma” and was a founder of what is today the American Cancer Society and laid the foundation of today`s Memorial Sloan Kettering Cancer Centre. Register online.

The EEC has been awarded funding for a further year

We are very grateful to the Bone Cancer Research Trust and Ewing's Sarcoma Research Trust for jointly supporting the EEC for a further year from December 2021. This will be the third year of support from The Ewing's Sarcoma Research Trust and the first year of funding from Bone Cancer Research Trust. The EEC does not receive funding from national organisations and is dependent on the support of fantastic charities like this to help us to continue with our mission to improve survival from Ewing sarcoma.

EEC PA is an author on a Ewing sarcoma publication

Yasmin Uhlenbruch, EEC patient advocate and member of the EEC Executive has contributed to a review of Ewing sarcoma by Stefan Zöllner and colleagues. The EEC is very encouraged to see this level of active involvement of patient advocates in research and dissemination. The paper, 'Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives' was published in the Journal of Clinical Medicine.

Another step closer to liquid biopsies for ES patients

Eleni Tomazou and colleagues have shown that sequencing of cell-free DNA from liquid biopsies of ES patients is feasible and can be used for the detection, classification and monitoring of disease. This study was part-funded by the EEC EU FP7 grant and the paper 'Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden' was published in Nature Communications.

Watch our films on the EURO EWING Consortium here. Thanks to all those members of the ES community who took part.

Patient advocacy has been a large part of the EEC project since 2013 and here are some of our current patient advocates talking about how they have contributed to our research. Watch the video here.

The EEC supported the Euro Ewing 2012 trial (now closed) and the rEECur trial (ongoing). Learn more about the EE2012 and rEECur trials by watching these films made by the EEC.



EEC membership

Membership is open to those in Europe and outside of Europe who are active in ES research/ treatment or patient advocacy. Before applying, you must have attended at least one EEC meeting. To apply for membership of the EEC, please complete the online form, and send your CV and two nominations from current EEC members to eec@ucl.ac.uk.

ASCO 2021

The American Society of Clinical Oncology (ASCO) conference was held virtually during 4 - 8 June 2021.

A downloadable version of the 2021 ASCO Annual Meeting Proceedings is now available and the abstracts for the sarcoma talks can be found here - ASCO sarcoma abstracts (pdf).

Links to abstracts and conclusions specific to Ewing sarcoma can be found here - ASCO Ewing sarcoma abstracts.

Recent meetings

  •  SIOP Europe Annual Meeting -  26-30 April 2021, virtual meeting including the following sessions:
    • 6th European bone sarcoma network meeting - Session 1 - Osteosarcoma (Thursday, April 29th, 14:15 - 15:45 CEST)
    • ITCC / Bone sarcoma Expert Session (operational meeting - by invitation only) (Friday, April 30th, 10:00 - 12:00 CEST)
    • 6th European bone sarcoma network / EuroEwing consortium meeting - Session 2 - Ewing sarcoma (Friday, April 30th, 14:15 - 15:45 CEST)